Establishment of a prediction model for disease progression within one year in newly diagnosed multiple myeloma patients

References

• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860–1873.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060.
   PubMed Web of Science ®Google Scholar
• Teras L-R, Carol-E D, James-R C, et al. 2016 US lymphoid malignancy statistics by world health organization subtypes. Ca-Cancer J Clin. 2016;66(6):443–459.
   PubMed Web of Science ®Google Scholar
• Siegel R-L, Kimberly-D M, Ahmedin J. Cancer statistics, 2016. Ca-Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676–681.
   PubMed Web of Science ®Google Scholar
• Liu Y. Multiple myeloma. China Academic Journal Electronic Publishing House. 2020.
   Google Scholar
• Cowan A-J, Christine A, Aleksandra B, et al. Global burden of multiple myeloma. JAMA Oncol. 2018;4(9):1221.
   PubMed Web of Science ®Google Scholar
• Wang D, Hao Y, Meng X, et al. Epidemiology and etiology of multiple myeloma. Int J Epidem and Infect Dis. 2018;45(04):277–280.
   Google Scholar
• Kristinsson S-Y, Landgren O, Dickman P-W, et al. Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25(15):1993–1999.
   PubMed Web of Science ®Google Scholar
• Turesson I, Velez R, Kristinsson S-Y, et al. Patterns of improved survival in patients With multiple myeloma in the twenty-first century: A population-based study. J Clin Oncol. 2010;28(5):830–834.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Brill IK, Omel J, et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Advances. 2017;1(4):282–287.
   PubMed Web of Science ®Google Scholar
• Swan D, Hayden PJ, Eikema D, et al. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: changing demographics and outcomes in European society for blood and marrow transplantation centres from 1995 to 2019. Br J Haematol. 2022.
   Web of Science ®Google Scholar
• Jennifer N. Brudno I-M-S-D, Dalia-Salem-Constance-Yuan S-S, Steven-A-Feldman-David M, et al. T cells genetically modified to express an anti – B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Emily-J S, Moryel-A Y, et al. The role of B-cell maturation antigen in the biology and management of, and as a potential therapeutic target in, multiple myeloma. Target Oncol. 2018;13(1):39–47.
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hematology. Multiple myeloma professional committee of Chinese medical doctor association. hematologist branch of Chinese medical doctor association. Guidelines for diagnosis and Treatment of Multiple Myeloma in China (revised in 2020). Chinese J Intern Med. 2020;59(5):341–346.
   PubMedGoogle Scholar
• Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071–3076.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C-S, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99(22):14374–14379.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C-S, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99(12):4525–4530.
   PubMed Web of Science ®Google Scholar
• Harousseau J-L, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91(11):1498–1505.
   PubMed Web of Science ®Google Scholar
• Lacy M-Q, Gertz M-A, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival With lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007;82(10):1179–1184.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337–1345.
   PubMed Web of Science ®Google Scholar
• Sekine L, Klarmann Ziegelmann P, Manica D, et al. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials. Crit Rev Oncol Hematol. 2019;143:102–116.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Otto V, Sabine S, et al. Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer. 2010;46(1):160–169.
   PubMed Web of Science ®Google Scholar
• Berridge M-J, Lipp P, Bootman M-D. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 2000;1(1):11–21.
   PubMed Web of Science ®Google Scholar
• Berridge M-J, Bootman M-D, Roderick H-L. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4(7):517–529.
   PubMed Web of Science ®Google Scholar
• Chen Y-F, Chen Y-T, Chiu W-T, et al. Remodeling of calcium signaling in tumor progression. J Biomed Sci. 2013;20:23.
   PubMed Web of Science ®Google Scholar
• Prevarskaya N, Skryma R, Shuba Y. Ion channels and the hallmarks of cancer. Trends Mol Med. 2010;16(3):107–121.
   PubMed Web of Science ®Google Scholar
• Chen Y-F, Lin P-C, Yeh Y-M, et al. Store-Operated Ca2+ entry in tumor progression: From molecular mechanisms to clinical implications. Cancers (Basel). 2019;11(7):899.
   PubMed Web of Science ®Google Scholar
• Fiorio P-A, Kondratska K, Prevarskaya N. STIM and ORAI proteins: crucial roles in hallmarks of cancer. Am J Physiol Cell Physiol. 2016;310(7):C509–C519.
   PubMed Web of Science ®Google Scholar
• Finn W-F, Kristin-Kvam A, Hjorth M, et al. Serum calcium is an independent predictor of quality of life in multiple myeloma. Eur J Haematol. 2007;78(1).
   Web of Science ®Google Scholar
• Corso A, Zappasodi P, Lazzarino M. Urinary proteins and renal dysfunction in patients with multiple myeloma. Biomed Pharmacother. 2002;56(3):139–143.
   PubMed Web of Science ®Google Scholar
• Prakash J, Mandal A-K, Vohra R, et al. Renal disease Is a prodrome of multiple myeloma: An analysis of 50 patients from eastern india. Ren Fail. 2009;31(4):267.
   PubMed Web of Science ®Google Scholar
• Miao P, Sheng S, Sun X, et al. Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy. IUBMB Life. 2013;65(11):904–910.
   PubMed Web of Science ®Google Scholar
• Dorneburg C, Matthias F, Thomas-F-E B, et al. LDHA in neuroblastoma Is associated with poor outcome and Its depletion decreases neuroblastoma growth independent of aerobic glycolysis. Clin cancer res. 2018;24(22):5772–5783.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Salvatore M, Vittorina Z, et al. Acute myeloid leukemia in the elderly: A critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymphoma. 1998;29(3-4):375–382.
   PubMed Web of Science ®Google Scholar
• Zhang C. Changes of lactate dehydrogenase levels in patients with acute leukemia. Asia-pacific Traditional Medicine. 2011;7(07):91–92.
   Google Scholar
• Bart Barlogie MD, Smallwood Leslie AE. High serum levels of lactic dehydrogenase identify a. American College of Physicians. 1989;110(7):521–525.
   Google Scholar
• Simonsson B, Brenning G, Et A. Prognostic value of serum lactic dehydrogenase(S-LDH)in multiple myeloma. Eur J Clin Invest. 1987;17(4):336–339.
   PubMed Web of Science ®Google Scholar
• Koukourakis M-I, Giatromanolaki A, Sivridis E, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011;17(14):4892–4900.
   PubMed Web of Science ®Google Scholar
• Urbanska K, Orzechowski A. Unappreciated role of LDHA and LDHB to control apoptosis and autophagy in tumor cells. Int J Mol Sci. 2019;20(9).
   PubMed Web of Science ®Google Scholar
• Koukourakis M-I, Giatromanolaki A, Panteliadou M, et al. Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. Br J Cancer. 2014;110(9):2217–2223.
   PubMed Web of Science ®Google Scholar
• Koukourakis M-I, Giatromanolaki A, Sivridis E, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011;17(14):4892–4900.
   PubMed Web of Science ®Google Scholar
• Ward P-S, Thompson C-B. Metabolic reprogramming: A cancer hallmark even warburg Did Not anticipate. Cancer Cell. 2012;21(3):297–308.
   PubMed Web of Science ®Google Scholar
• Yao J-C, Phan A-T, Chang D-Z, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced Low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol. 2008;26(26):4311–4318.
   PubMed Web of Science ®Google Scholar
• Wang S, Xie J, Li J, et al. Cisplatin suppresses the growth and proliferation of breast and cervical cancer cell lines by inhibiting integrin beta5-mediated glycolysis. Am J Cancer Res. 2016;6(5):1108–1117.
   PubMed Web of Science ®Google Scholar
• Sun W, Zhang X, Ding X, et al. Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma. PLoS One. 2015;10(5):e0125976.
   PubMed Web of Science ®Google Scholar
• Leiblich A, Cross S-S, Catto J-W, et al. Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene. 2006;25(20):2953–2960.
   PubMed Web of Science ®Google Scholar
• Jin Mei Qiu, Juan Gong, Qing Chi Xie, et al. The role of lactate dehydrogenase in tumor metabolism and the development of antitumor drugs targeting lactate dehydrogenase. Cancer Res Prev Treat. 2020;47(12):82–87.
   Google Scholar
• Takeo N, Fujiwara S, Sakai T, et al. Hereditary lactate dehydrogenase M-subunit deficiency with late-developing pustular psoriasis-like lesions. J Dermatol. 2016;43(12):1429–1432.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M-A, Barlogie B, Smith T-L, et al. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115(12):931–935.
   PubMed Web of Science ®Google Scholar
• Suguro M, Kanda Y, Yamamoto R, et al. High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma. Am J Hematol. 2000;65(2):132–135.
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Gika D, Symeonidis A, et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol. 2005;75(5):370–375.
   PubMed Web of Science ®Google Scholar
• Feng J-F, Huang Y, Liu J-S. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther. 2013;6:1605–1612.
   PubMed Web of Science ®Google Scholar
• de Martino M, Allan-J P, Sebastian H, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urology. 2013;190(6):1999–2004.
   PubMed Web of Science ®Google Scholar
• Xue T-C, Lan Z, Xiao-Yin X, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: A meta-analysis. PloS one. 2014;9(5):e96072.
   PubMed Web of Science ®Google Scholar
• Zhuangzhuang Cui, Yuanyuan Zhang, Ping Bei, et al. Prognostic significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for overall survival and progression-free survival in newly diagnosed multiple myeloma patients. J PLA med college. 2019;40(2):121–126.
   Google Scholar
• Wang J, Zhou X, Liu Y, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis. PLoS One. 2017;12(4):e176008.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30:677–706.
   PubMed Web of Science ®Google Scholar
• Dvorak H-F. Tumors: Wounds that Do Not heal. N Engl J Med. 1986;315(26):1650–1659.
   PubMed Web of Science ®Google Scholar
• Kokcu A, Kurtoglu E, Celik H, et al. May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer?. Asian Pac J Cancer Prev. 2014;15(22):9781–9784.
   PubMedGoogle Scholar
• Greenberg A-J, Vachon C-M, Rajkumar S-V. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2012;26(4):609–614.
   PubMed Web of Science ®Google Scholar
• Sun J, Mou N, Mou J, et al. Significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio changes in patients with multiple myeloma. Chinese J Exper Hematology. 2019;27(04):1185–1189.
   Google Scholar